Abstract:Background: Volumetric alterations of subcortical structures as predictors of antipsychotic treatment response have been previously corroborated, but less is known about whether their morphological covariance relates to treatment outcome and is driven by gene expression and epigenetic modifications. Methods: Subcortical volumetric covariance was analyzed by using baseline T1-weighted magnetic resonance imaging (MRI) in 38 healthy controls and 38 drug-naïve first-episode schizophrenia patients. Patients were treated with 8-week risperidone monotherapy and divided into responder and non-responder groups according to the Remission in Schizophrenia Working Group (RSWG). We utilized partial least squares (PLS) regression to examine the spatial associations between gene expression of subcortical structures from a publicly available transcriptomic dataset and between-group variances of structural covariance. The peripheral DNA methylation (DNAm) status of a gene of interest (GOI), overlapping between genes detected in the PLS and 108 schizophrenia candidate gene loci previously reported, was examined in parallel with MRI scanning. Results: In the psychotic symptom dimension, non-responders had a higher baseline structural covariance in the putamen–hippocampus–pallidum–accumbens pathway compared with responders. For disorganized symptoms, significant differences in baseline structural covariant connections were found in the putamen–hippocampus–pallidum–thalamus circuit between the two subgroups. The imaging variances related to psychotic symptom response were spatially related to the expression of genes enriched in neurobiological processes and dopaminergic pathways. The DNAm of GOI demonstrated significant associations with patients' improvement of psychotic symptoms. Conclusion: Baseline subcortical structural covariance and peripheral DNAm may relate to antipsychotic treatment response. Phenotypic variations in subcortical connectome related to psychotic symptom response may be transcriptomically and epigenetically underlaid. This study defines a roadmap for future studies investigating multimodal imaging epigenetic biomarkers for treatment response in schizophrenia.

Omics in Schizophrenia: Current Progress and Future Directions of Antipsychotic Treatments

Protocol for a Pharmacogenomic Study on Individualised Antipsychotic Drug Treatment for Patients with Schizophrenia.

Integrative Omics of Schizophrenia: from Genetic Determinants to Clinical Classification and Risk Prediction

[Research progress of transcriptomics and proteomics in schizophrenia]

DNA Methylation in Schizophrenia: Progress and Challenges

What Remains to Be Discovered in Schizophrenia Therapeutics: Contributions by Advancing the Molecular Mechanisms of Drugs for Psychosis and Schizophrenia

Refining antipsychotic treatment strategies in schizophrenia: discovery of genetic biomarkers for enhanced drug response prediction

Predictive Biomarkers for Antipsychotic Treatment Response in Early Phase of Schizophrenia: Multi-Omic Measures Linking Subcortical Covariant Network, Transcriptomic Signatures, and Peripheral Epigenetics

Unveiling Promising Neuroimaging Biomarkers for Schizophrenia Through Clinical and Genetic Perspectives

Consensus on Potential Biomarkers Developed for Use in Clinical Tests for Schizophrenia

Neuroimaging biomarkers for drug discovery and development in Schizophrenia

The genomics of schizophrenia: Shortcomings and solutions

Current emerging therapeutic targets and clinical investigational agents for schizophrenia: Challenges and opportunities

Potential diagnostic biomarkers for schizophrenia.

Novel approaches in schizophrenia-from risk factors and hypotheses to novel drug targets

Current Status and Prospect of Biomarker Research for Schizophrenia

Toward recovery in schizophrenia: Current concepts, findings, and future research directions

Precision medicine for psychotic disorders: objective assessment, risk prediction, and pharmacogenomics

Research Progress on the Correlation Between Epigenetics and Schizophrenia

Role of different omics data in the diagnosis of schizophrenia disorder: A machine learning study

Functional magnetic resonance imaging in schizophrenia: current evidence, methodological advances, limitations and future directions